{"name":"NextPoint Therapeutics, Inc.","slug":"nextpoint-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPSG1pdXRUWmJxSTNqMW8zS2hOM3pOMXpDR2xqVkRtZ0ljeEpfekNfbTlwYURkVjgtNnhFeVBpYmZGWnlrTml1RG5mQW5oWWFrbEpSeGJNUGhQSEx6V0g4RFR5ckxlWlQ0WWlSQkd1T1hjMGFaNlRMU2V1OElESDk2Vnl2bk1zTldhTU1nZW0zRFlCR0xMQ1UyOVZ2RWtnM2xCMmVCTlhvcEVneUF6azdjRWkyQmdkTl81cXYyaXRScDlOSElLNmpQWjQxQ0hmb2NTMm0zVDBfMjlJb1R5dlJWbThlaG81SWxpbXc0N0U4dUdDbUJIRXlZRGJMV2xQaFd5YU9iRjRHUG5rOGE1UG9z?oc=5","date":"2026-02-09","type":"pipeline","source":"businesswire.com","summary":"NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors - businesswire.com","headline":"NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOYXM2QTdfbmJwVURFUnBPWXp0REUyblpQNXVXQ1NrY2IwVjdlQzFGaGhmcmZiclZoU0RBQzU0YV9UNmltUVRMX0ZHMEFhU3FzemVjQ1FrcmZ6YllSdmpqM3ROa19fQU1HTzc3SHBBQmFNYXgwaEdPZUNSX3I3RHd0N040MHRiSG95THF6M2FtMDhwQUxSNHhWQWpJNDZvdW9tLU5fT2k3UmQ2MC1kYXZ4ZkVPcC1lMlhHWlhWaEtKOG9HYjFTeFJvdzk2djd1RjVTQUR3LU1sclEwSzJiYUFBN3F3aG1tbXkzckFiT2xzV2VfQjJEY2tNRy02dEp3elFYQmg5Njk0ZThfMEs4eEhYaDhXMFRqVWd2VXdjMXZER0JQVXVVY0VrNGpn?oc=5","date":"2025-07-30","type":"pipeline","source":"prnewswire.com","summary":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight - prnewswire.com","headline":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technologi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNX3ZfOUF1SV9odkQ5X1gteldKYVNQZXc4MHdvSUtZZzU5SURON2RYZHQ2LXo1Q003VEZZeFBXX2VoaEtlVXdrRzBxTTdfRmxESWdjSkU3TjU0ZERpU245c2xOcGRTWVNYamNfVF9nc2Q2VkZTZjl2YXA5eF80VUdfNjhrdFF3SjJqbUQ3R1FrM3JJUVdoNnhEUTI2WkZ0RkhqTDcyUm5fa1NKaXVpWXpWZEpBTy1DUHF6bG9oLWtn?oc=5","date":"2025-05-12","type":"pipeline","source":"Contract Pharma","summary":"Aera Therapeutics Appoints Paul Conrad Chief Business and Financial Officer - Contract Pharma","headline":"Aera Therapeutics Appoints Paul Conrad Chief Business and Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxORlVKeklUSDJuTWo2WmtSNWxSeE1tdzFaVUZfYU5pS1JBNkJhT0laMmFQdDlHMHBDb2REdEw1cGJrNk1OU1Z1RlRHaV9hVFZRU2tQcWk1bVRWV0tndHBQWkcxZDVPY1hTWTNRaU82OWNtWHJEZ2pCTUlnNVEwYTJwQXV4aERBeXVwTTFUOGJ4cWJtX05aZENwaUdRdW5qOUN1VlZ6aFNETDVKajZCSlFUQ2JRMEltWkRwT3ZKN1hlXzdXVDVUektqRGx5Wm9uR0ZjR2dwMng1aUNKNXUzZUI3bllKM1YwZmtRZW1oWkRjRUhCUWVLZnYwTUlsbkhnUURYSEVPV00xOFVCN3BQeFI4a0w4LXRNTDVIbEFkOXNGQVFiazltSDlCY0Jwd0l1T2Y4LVE?oc=5","date":"2025-04-25","type":"trial","source":"businesswire.com","summary":"NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025 - businesswire.com","headline":"NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPanhOcXd1NU5pNHlCY045NWR6LVdnU0NCYm0wSnpOeUR1dUExVzcwU3lfSVFINkJlMF9iLTdnWWlwa3dNME9OVndRY2pQT1FsRmE1VC1PZHl3N2w2a09ZRE83NEpFOHdnb0JaWHlqV1EtdjhYdnFweEhXNG9vUjF2YzRfaXczRlYzQ3FtQlpfeTlwSDVJT3FDdHdBbzU2SFRQRThvS2NGc0trX2VWZW9Kb0tnVzE2bXhSUVAzUHRRV2xnTlRkMGpxc0xBTlN0WmhTeUR6MzZSMWdZQlJUby1nR0pVdFI5MkU?oc=5","date":"2025-02-21","type":"pipeline","source":"Citeline News & Insights","summary":"Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances - Citeline News & Insights","headline":"Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOV2JzNjBwRkc5aTVkZU8tWDR1bVItNEt3Z3dOWlBqT010Y2dSVWNkcGlYMlJTaThCeml5bTBfMWlBcGRScm9xbGF0dUgwRXBfX19zYWRrMElfaktRVjJBZWhNMnJIS3Z1anlvV3JzelJHX2ZSLW5wbVphd2xaVkd3S0RMVHhBMnBPc1cyM09OWGhYQWRFNjVhTFZMQmhvYmJYQzZpYW1pX2FYbWxRaW9ISW1OdnBGTlk0bjBlcE5IME8yNnJLOU05S2s4dDFweEIwUWpnTGQ1V3VGWktqQ0pSR2V3?oc=5","date":"2024-09-09","type":"pipeline","source":"BioPharma APAC","summary":"NextPoint Therapeutics Introduces NPX372, a Novel T Cell Engager Targeting B7-H7 Axis in Solid Tumors - BioPharma APAC","headline":"NextPoint Therapeutics Introduces NPX372, a Novel T Cell Engager Targeting B7-H7 Axis in Solid Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOaVkwblp0VUJKSlg4RWpnSG1JT2xkazJERHREZUxIRHVtRXJnWllaQlpvdktwZ09PNWgzOTV5dGY0SGR0ZlJFTW90YlJTb2VqQXJJTjBwbWVTVkFHcjdZeERRTnpnREF0OGN2MjdZRmxhdnFfejVVbFYwenVITTVlcmZYeWktSWYyczZadmo1QXltTkpya0U4akdyd1ZsSjliaTNpNWRTdFk?oc=5","date":"2024-09-06","type":"pipeline","source":"BioWorld News","summary":"Nextpoint unveils T-cell engager for B7-H7-positive solid tumors - BioWorld News","headline":"Nextpoint unveils T-cell engager for B7-H7-positive solid tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE80Vm5UT2cyRWZ3Yk5ZR1BDeXl3Sk1rVWp2U2s3QWpvZTBGbVpkb2NUSEg0Xy1pSFV4NlJYTjdjUUNHQ0w4UzVzM3lFVjV0enJSZG93N3JnY1UtMkZNbFlqRjJfemlNSFdZaXhqdUdwX3haQQ?oc=5","date":"2024-05-02","type":"pipeline","source":"Time Magazine","summary":"Ivan Cheung - Time Magazine","headline":"Ivan Cheung","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE1vODVEZ2Joa3VmOXlpcW9LWVlmMGJnVXY1N1NodndpSldBYUQ3QWM2SFlQWWl3WnRmbnFKUTNyRnFTZHA3UC1aVDJEMFd6WjI3bUh2am1nMll1NUk4UWs2eVI1MXJnTDZ5WUw2clY0WWVra3pORFVUN01n?oc=5","date":"2024-02-21","type":"trial","source":"Clinical Trials Arena","summary":"NextPoint doses first subject in Phase I solid tumour treatment trial - Clinical Trials Arena","headline":"NextPoint doses first subject in Phase I solid tumour treatment trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNMWNGM1c3MVVPQ01KajlScVVMYnBxa25hRDZ0U2FQQnhJLUlxUWRrcC1yWm1sTXF1SWZXN3hLNi1uZjRodUdEV18tZ094UEdlci1PUHVWVFFZTEJxUW02NTY0WTRtYy11VWNya0RiQ3hpYVdqSV8zVzdKOFFZTWNIbUZJS0VzNTVZMTVZY2NxZHJDcG5zaTRwaTBoNkd4cVFaNUFiUHdB?oc=5","date":"2024-02-02","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Ex-Eisai leader Ivan Cheung tapped to be new CEO of NextPoint - Fierce Biotech","headline":"Chutes & Ladders—Ex-Eisai leader Ivan Cheung tapped to be new CEO of NextPoint","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPYm5fQjd5QTZWSVRERjBDTlE0dmdiVzZpbGZtMEVHY2xTc1VneGlWRkJJTGpxOTBVY3MwQVBrWTdXYUNBVXlvM1hjNDMxR2NSV1RKTnlIZGpxLU5KaVlWbS1rd0hGNnlHTXFnWWxFR2tJZG1pM0Q4N1ZWdjIxU2ltTFgwQU5od2RRN3NGNmt0WWp0U2ZCNTI5YWduLUpSdUo4UDJzZlhuNA?oc=5","date":"2024-02-01","type":"pipeline","source":"Fierce Biotech","summary":"After Eisai retirement, Ivan Cheung is back to lead Massachusetts biotech - Fierce Biotech","headline":"After Eisai retirement, Ivan Cheung is back to lead Massachusetts biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxORnF5RnMxS0FtbFpJTnhVYWl4NlI1S0YyRFNQelYtZFFCVTN4eHNiRXBQRVpWV2FHMGZwcUV3V2FMYmJRNmdLZHVVZmFJdnVIbkd1ZS15dDMxUVVPVUw2N2ZTdGpNcEVLN0ZwSkRsRk9NQnhOeFVMeFVYbjgyV2w5YlRBcFhXUVRxTG1WLURuLVREY2VXRGZyYzdmUVdGNEJpUjNjblhB?oc=5","date":"2023-03-21","type":"pipeline","source":"citybiz","summary":"Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors - citybiz","headline":"Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}